Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula lineal:
HOOCCH2CH2COCOONa
Número CAS:
Peso molecular:
168.08
UNSPSC Code:
12352204
NACRES:
NA.32
PubChem Substance ID:
EC Number:
244-836-6
Beilstein/REAXYS Number:
4597521
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleproduct line
BioUltra
Quality Level
assay
≥98% (perchloric acid titration)
form
powder
impurities
≤0.0005% Phosphorus (P), ≤0.1% Insoluble matter
solubility
H2O: 0.5 M, clear, colorless
anion traces
chloride (Cl-): ≤0.05%, sulfate (SO42-): ≤0.05%
cation traces
Al: ≤0.0005%, Ca: ≤0.001%, Cu: ≤0.0005%, Fe: ≤0.0005%, K: ≤0.005%, Mg: ≤0.0005%, NH4+: ≤0.05%, Pb: ≤0.001%, Zn: ≤0.0005%
storage temp.
2-8°C
SMILES string
[Na+].OC(=O)CCC(=O)C([O-])=O
InChI
1S/C5H6O5.Na/c6-3(5(9)10)1-2-4(7)8;/h1-2H2,(H,7,8)(H,9,10);/q;+1/p-1
InChI key
MOTOGHHLNTXPTI-UHFFFAOYSA-M
Application
α-Ketoglutaric acid sodium salt has been used in the human kynurenine amino transferase II (KAT II) inhibition spectra assay.
Biochem/physiol Actions
α-Ketoglutaric acid is the precursor for L-glutamic acid.
α-Ketoglutaric acid is a key intermediate in the TCA Cycle. It also plays an important role in preventing nitrogen overload by combining with nitrogen released within the cell.
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Structure-based design of irreversible human KAT II inhibitors: Discovery of new potency-enhancing interactions
Tuttle JB, et al.
ACS Medicinal Chemistry Letters, 4(1), 37-40 (2012)
Amino Acids in Therapy: A Guide to the Therapeutic Application of Protein Constituents, 34-34 (1985)
Piotr Dobrowolski et al.
Nutrition (Burbank, Los Angeles County, Calif.), 29(3), 556-561 (2012-12-12)
Proton-pump inhibitors, such as omeprazole, are widely used in the prevention and treatment of gastroesophageal diseases. However, an association between proton-pump inhibitors and the increased risk of bone fractures has been observed, especially in patients treated for extended periods. Conversely